{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T14:22:55Z","timestamp":1778768575454,"version":"3.51.4"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T00:00:00Z","timestamp":1742342400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T00:00:00Z","timestamp":1742342400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Divers"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s11030-025-11157-y","type":"journal-article","created":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T14:25:37Z","timestamp":1742394337000},"page":"3425-3448","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Integrated AI and machine learning pipeline identifies novel WEE1 kinase inhibitors for targeted cancer therapy"],"prefix":"10.1007","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5088-9683","authenticated-orcid":false,"given":"Jaikanth","family":"Chandrasekaran","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dhanushya","family":"Gopal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lokesh Vishwa","family":"Sureshkumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Infant Xavier","family":"Santhiyagu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Varsha","family":"Senthil Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bhuvaneshwari","family":"Munuswamy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beevi Fathima Harshatha Mohamed You","family":"Gani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohit","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,19]]},"reference":[{"issue":"3","key":"11157_CR1","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.3390\/ijms23031155","volume":"23","author":"J Gyamfi","year":"2022","unstructured":"Gyamfi J, Kim J, Choi J (2022) Cancer as a metabolic disorder. Int J Mol Sci 23(3):1155. https:\/\/doi.org\/10.3390\/ijms23031155","journal-title":"Int J Mol Sci"},{"key":"11157_CR2","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.semcancer.2021.03.025","volume":"83","author":"JE Lee","year":"2022","unstructured":"Lee JE, Kim M-Y (2022) Cancer epigenetics: past, present and future. Semin Cancer Biol 83:4\u201314. https:\/\/doi.org\/10.1016\/j.semcancer.2021.03.025","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"11157_CR3","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan D (2022) Hallmarks of cancer: new dimensions. Cancer Discov 12(1):31\u201346. https:\/\/doi.org\/10.1158\/2159-8290.CD-21-1059","journal-title":"Cancer Discov"},{"key":"11157_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.mrfmmm.2020.111694","volume":"819","author":"CR Elb\u00e6k","year":"2020","unstructured":"Elb\u00e6k CR, Petrosius V, S\u00f8rensen CS (2020) WEE1 kinase limits CDK activities to safeguard DNA replication and mitotic entry. Mutat Res\/Fundam Mol Mech Mutagen 819:111694. https:\/\/doi.org\/10.1016\/j.mrfmmm.2020.111694","journal-title":"Mutat Res\/Fundam Mol Mech Mutagen"},{"key":"11157_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.828684","volume":"12","author":"AB Bukhari","year":"2022","unstructured":"Bukhari AB, Chan GK, Gamper AM (2022) Targeting the DNA damage response for cancer therapy by inhibiting the kinase WEE1. Front Oncol 12:828684. https:\/\/doi.org\/10.3389\/fonc.2022.828684","journal-title":"Front Oncol"},{"issue":"1","key":"11157_CR6","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s13045-020-00959-2","volume":"13","author":"A Ghelli Luserna di Rora","year":"2020","unstructured":"Ghelli Luserna di Rora A, Cerchione C, Martinelli G, Simonetti G (2020) A WEE1 family business: regulation of mitosis, cancer progression, and therapeutic target. J Hematol Oncol 13(1):126. https:\/\/doi.org\/10.1186\/s13045-020-00959-2","journal-title":"J Hematol Oncol"},{"issue":"1","key":"11157_CR7","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41580-021-00404-3","volume":"23","author":"HK Matthews","year":"2021","unstructured":"Matthews HK, Bertoli C, de Bruin RAM (2021) Cell cycle control in cancer. Nat Rev Mol Cell Biol 23(1):74\u201388. https:\/\/doi.org\/10.1038\/s41580-021-00404-3","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"3","key":"11157_CR8","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.3390\/ijms24032026","volume":"24","author":"C Sarkar","year":"2023","unstructured":"Sarkar C et al (2023) Artificial intelligence and machine learning technology driven modern drug discovery and development. Int J Mol Sci 24(3):2026. https:\/\/doi.org\/10.3390\/ijms24032026","journal-title":"Int J Mol Sci"},{"issue":"7","key":"11157_CR9","doi-asserted-by":"publisher","first-page":"649","DOI":"10.2174\/1568026621666210121153413","volume":"21","author":"DM Herrera-Ibata","year":"2021","unstructured":"Herrera-Ibata DM (2021) Machine learning and perturbation theory machine learning (PTML) in medicinal chemistry, biotechnology, and nanotechnology. Curr Top Med Chem 21(7):649\u2013660. https:\/\/doi.org\/10.2174\/1568026621666210121153413","journal-title":"Curr Top Med Chem"},{"key":"11157_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10020491","author":"VV Kleandrova","year":"2022","unstructured":"Kleandrova VV, Speck-Planche A (2022) PTML modeling for pancreatic cancer research: in silico design of simultaneous multi-protein and multi-cell inhibitors. Biomedicines. https:\/\/doi.org\/10.3390\/biomedicines10020491","journal-title":"Biomedicines"},{"key":"11157_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/biom11121832","author":"A Speck-Planche","year":"2021","unstructured":"Speck-Planche A, Kleandrova VV, Scotti MT (2021) In silico drug repurposing for anti-inflammatory therapy: virtual search for dual inhibitors of caspase-1 and TNF-alpha. Biomolecules. https:\/\/doi.org\/10.3390\/biom11121832","journal-title":"Biomolecules"},{"issue":"7","key":"11157_CR12","doi-asserted-by":"publisher","first-page":"661","DOI":"10.2174\/1568026621666210119112845","volume":"21","author":"VV Kleandrova","year":"2021","unstructured":"Kleandrova VV, Scotti MT, Scotti L, Speck-Planche A (2021) Multi-target drug discovery via PTML modeling: applications to the design of virtual dual inhibitors of CDK4 and HER2. Curr Top Med Chem 21(7):661\u2013675. https:\/\/doi.org\/10.2174\/1568026621666210119112845","journal-title":"Curr Top Med Chem"},{"key":"11157_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/ph16060891","author":"A Blanco-Gonzalez","year":"2023","unstructured":"Blanco-Gonzalez A et al (2023) The role of AI in drug discovery: challenges, opportunities, and strategies. Pharmaceuticals (Basel). https:\/\/doi.org\/10.3390\/ph16060891","journal-title":"Pharmaceuticals (Basel)"},{"issue":"1","key":"11157_CR14","doi-asserted-by":"publisher","first-page":"22104","DOI":"10.1038\/s41598-020-78537-2","volume":"10","author":"W Jeon","year":"2020","unstructured":"Jeon W, Kim D (2020) Autonomous molecule generation using reinforcement learning and docking to develop potential novel inhibitors. Sci Rep 10(1):22104. https:\/\/doi.org\/10.1038\/s41598-020-78537-2","journal-title":"Sci Rep"},{"issue":"7","key":"11157_CR15","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1021\/jm901137j","volume":"53","author":"JB Baell","year":"2010","unstructured":"Baell JB, Holloway GA (2010) New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. J Med Chem 53(7):2719\u20132740. https:\/\/doi.org\/10.1021\/jm901137j","journal-title":"J Med Chem"},{"issue":"5","key":"11157_CR16","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1021\/ci100050t","volume":"50","author":"D Rogers","year":"2010","unstructured":"Rogers D, Hahn M (2010) Extended-connectivity fingerprints. J Chem Inf Model 50(5):742\u2013754. https:\/\/doi.org\/10.1021\/ci100050t","journal-title":"J Chem Inf Model"},{"key":"11157_CR17","doi-asserted-by":"publisher","unstructured":"McInnes L, Healy J, Melville J (2018) UMAP: uniform manifold approximation and projection for dimension reduction. https:\/\/doi.org\/10.48550\/arXiv.1802.03426","DOI":"10.48550\/arXiv.1802.03426"},{"key":"11157_CR18","doi-asserted-by":"publisher","unstructured":"Ashabi A, Sahibuddin SB, Salkhordeh Haghighi M (2020) The systematic review of K-means clustering algorithm. In: Proceedings of the 2020 9th international conference on networks, communication and computing, 2020, pp 13\u201318. https:\/\/doi.org\/10.1145\/3447654.3447657","DOI":"10.1145\/3447654.3447657"},{"issue":"15","key":"11157_CR19","doi-asserted-by":"publisher","first-page":"2887","DOI":"10.1021\/jm9602928","volume":"39","author":"GW Bemis","year":"1996","unstructured":"Bemis GW, Murcko MA (1996) The properties of known drugs. 1. Molecular frameworks. J Med Chem 39(15):2887\u20132893. https:\/\/doi.org\/10.1021\/jm9602928","journal-title":"J Med Chem"},{"issue":"1","key":"11157_CR20","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1158\/1078-0432.CCR-21-0158","volume":"28","author":"KN Moore","year":"2022","unstructured":"Moore KN et al (2022) Adavosertib with chemotherapy in patients with primary platinum-resistant ovarian, fallopian tube, or peritoneal cancer: an open-label, four-arm, phase II study. Clin Cancer Res 28(1):36\u201344. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-0158","journal-title":"Clin Cancer Res"},{"issue":"12_Supplement","key":"11157_CR21","doi-asserted-by":"publisher","first-page":"CT029","DOI":"10.1158\/1538-7445.AM2022-CT029","volume":"82","author":"F Meric-Bernstam","year":"2022","unstructured":"Meric-Bernstam F et al (2022) Abstract CT029: safety and clinical activity of single-agent ZN-c3, an oral WEE1 inhibitor, in a phase 1 trial in subjects with recurrent or advanced uterine serous carcinoma (USC). Cancer Res 82(12_Supplement):CT029. https:\/\/doi.org\/10.1158\/1538-7445.AM2022-CT029","journal-title":"Cancer Res"},{"key":"11157_CR22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.3120","author":"KP Papadopoulos","year":"2024","unstructured":"Papadopoulos KP et al (2024) Results of a phase 1, dose-finding study of Debio 0123 as monotherapy in adult patients with advanced solid tumors: safety, pharmacokinetic, and preliminary antitumor activity data. J Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.3120","journal-title":"J Clin Oncol"},{"key":"11157_CR23","doi-asserted-by":"publisher","first-page":"S466","DOI":"10.1016\/j.annonc.2023.09.1848","volume":"34","author":"C Lin","year":"2023","unstructured":"Lin C et al (2023) 662MO Phase I, multi-center, dose-escalation and dose-expansion study of IMP7068, a WEE1 inhibitor, in patients with advanced solid tumors. Ann Oncol 34:S466. https:\/\/doi.org\/10.1016\/j.annonc.2023.09.1848","journal-title":"Ann Oncol"},{"issue":"5","key":"11157_CR24","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1021\/acsmedchemlett.2c00481","volume":"14","author":"S Guler","year":"2023","unstructured":"Guler S et al (2023) Selective WEE1 inhibitors led to antitumor activity in vitro and correlated with myelosuppression. ACS Med Chem Lett 14(5):566\u2013576. https:\/\/doi.org\/10.1021\/acsmedchemlett.2c00481","journal-title":"ACS Med Chem Lett"},{"key":"11157_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13321-015-0069-3","volume":"7","author":"D Bajusz","year":"2015","unstructured":"Bajusz D, R\u00e1cz A, H\u00e9berger K (2015) Why is Tanimoto index an appropriate choice for fingerprint-based similarity calculations? J Cheminform 7:1\u201313. https:\/\/doi.org\/10.1186\/s13321-015-0069-3","journal-title":"J Cheminform"},{"key":"11157_CR26","doi-asserted-by":"publisher","unstructured":"Landrum G (2019) RDKit: open-source cheminformatics from machine learning to chemical registration. In: Abstracts of papers of the American Chemical Society, 2019, vol 258. American Chemical Society, Washington, DC. https:\/\/doi.org\/10.5281\/zenodo.591637","DOI":"10.5281\/zenodo.591637"},{"issue":"7","key":"11157_CR27","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1021\/jm0306430","volume":"47","author":"RA Friesner","year":"2004","unstructured":"Friesner RA et al (2004) (2004) Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem 47(7):1739\u20131749. https:\/\/doi.org\/10.1021\/jm0306430","journal-title":"J Med Chem"},{"key":"11157_CR28","doi-asserted-by":"publisher","unstructured":"Bowers KJ et al (2006) Scalable algorithms for molecular dynamics simulations on commodity clusters. In: Proceedings of the 2006 ACM\/IEEE conference on supercomputing, 2006, p 84-es. https:\/\/doi.org\/10.1145\/1188455.1188544","DOI":"10.1145\/1188455.1188544"},{"key":"11157_CR29","doi-asserted-by":"publisher","DOI":"10.1007\/s11030-024-10819-7","author":"D Gopal","year":"2024","unstructured":"Gopal D, Muthuraj R, Balaya RDA, Kanekar S, Ahmed I, Chandrasekaran J (2024) Computational discovery of novel FYN kinase inhibitors: a cheminformatics and machine learning-driven approach to targeted cancer and neurodegenerative therapy. Mol Divers. https:\/\/doi.org\/10.1007\/s11030-024-10819-7","journal-title":"Mol Divers"},{"key":"11157_CR30","doi-asserted-by":"publisher","DOI":"10.1080\/07391102.2024.2305316","author":"R Muthuraj","year":"2024","unstructured":"Muthuraj R, Gopal D, Ahmed I, Chandrasekaran J (2024) Insightful t-SNE guided exploration spotlighting Palbociclib and Ribociclib analogues as novel WEE1 kinase inhibitory candidates. J Biomol Struct Dyn. https:\/\/doi.org\/10.1080\/07391102.2024.2305316","journal-title":"J Biomol Struct Dyn"},{"key":"11157_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1758-2946-1-8","volume":"1","author":"P Ertl","year":"2009","unstructured":"Ertl P, Schuffenhauer A (2009) Estimation of synthetic accessibility score of drug-like molecules based on molecular complexity and fragment contributions. J Cheminform 1:1\u201311. https:\/\/doi.org\/10.1186\/1758-2946-1-8","journal-title":"J Cheminform"},{"issue":"12","key":"11157_CR32","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1021\/ja00402a071","volume":"103","author":"SH Bertz","year":"1981","unstructured":"Bertz SH (1981) The first general index of molecular complexity. J Am Chem Soc 103(12):3599\u20133601. https:\/\/doi.org\/10.1021\/ja00402a071","journal-title":"J Am Chem Soc"},{"issue":"22","key":"11157_CR33","doi-asserted-by":"publisher","first-page":"10026","DOI":"10.1021\/acs.jmedchem.9b00004","volume":"62","author":"YA Ivanenkov","year":"2019","unstructured":"Ivanenkov YA, Zagribelnyy BA, Aladinskiy VA (2019) Are we opening the door to a new era of medicinal chemistry or being collapsed to a chemical singularity? Perspective. J Med Chem 62(22):10026\u201310043. https:\/\/doi.org\/10.1021\/acs.jmedchem.9b00004","journal-title":"J Med Chem"},{"issue":"10271","key":"11157_CR34","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/S0140-6736(20)32554-X","volume":"397","author":"S Lheureux","year":"2021","unstructured":"Lheureux S et al (2021) Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet 397(10271):281\u2013292. https:\/\/doi.org\/10.1016\/S0140-6736(20)32554-X","journal-title":"Lancet"},{"issue":"4","key":"11157_CR35","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1158\/1078-0432.CCR-20-3089","volume":"27","author":"TE Keenan","year":"2021","unstructured":"Keenan TE et al (2021) Clinical efficacy and molecular response correlates of the WEE1 inhibitor adavosertib combined with cisplatin in patients with metastatic triple-negative breast cancer. Clin Cancer Res 27(4):983\u2013991. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-3089","journal-title":"Clin Cancer Res"},{"issue":"29","key":"11157_CR36","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1200\/JCO.19.00730","volume":"37","author":"KC Cuneo","year":"2019","unstructured":"Cuneo KC et al (2019) Dose escalation trial of the WEE1 inhibitor adavosertib (AZD1775) in combination with gemcitabine and radiation for patients with locally advanced pancreatic cancer. J Clin Oncol 37(29):2643\u20132650. https:\/\/doi.org\/10.1200\/JCO.19.00730","journal-title":"J Clin Oncol"},{"issue":"1","key":"11157_CR37","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1021\/acschembio.7b00903","volume":"13","author":"JB Baell","year":"2018","unstructured":"Baell JB, Nissink JWM (2018) Seven year itch: pan-assay interference compounds (PAINS) in 2017\u2014utility and limitations. ACS Chem Biol 13(1):36\u201344. https:\/\/doi.org\/10.1021\/acschembio.7b00903","journal-title":"ACS Chem Biol"},{"issue":"11","key":"11157_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2022.103356","volume":"27","author":"J Yang","year":"2022","unstructured":"Yang J, Cai Y, Zhao K, Xie H, Chen X (2022) Concepts and applications of chemical fingerprint for hit and lead screening. Drug Discov Today 27(11):103356. https:\/\/doi.org\/10.1016\/j.drudis.2022.103356","journal-title":"Drug Discov Today"},{"issue":"18","key":"11157_CR39","doi-asserted-by":"publisher","first-page":"7863","DOI":"10.1021\/acs.jmedchem.7b00996","volume":"60","author":"J-Y Zhu","year":"2017","unstructured":"Zhu J-Y et al (2017) Structural basis of wee kinases functionality and inactivation by diverse small molecule inhibitors. J Med Chem 60(18):7863\u20137875. https:\/\/doi.org\/10.1021\/acs.jmedchem.7b00996","journal-title":"J Med Chem"},{"issue":"4","key":"11157_CR40","first-page":"61","volume":"24","author":"CH Heip","year":"1998","unstructured":"Heip CH, Herman PM, Soetaert K (1998) Indices of diversity and evenness. Oceanis 24(4):61\u201388","journal-title":"Oceanis"}],"container-title":["Molecular Diversity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-025-11157-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11030-025-11157-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-025-11157-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T13:05:41Z","timestamp":1752152741000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11030-025-11157-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,19]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["11157"],"URL":"https:\/\/doi.org\/10.1007\/s11030-025-11157-y","relation":{},"ISSN":["1381-1991","1573-501X"],"issn-type":[{"value":"1381-1991","type":"print"},{"value":"1573-501X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,19]]},"assertion":[{"value":"28 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Authors declare no conflict of interest in any form.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}